Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Faraday Future Intelligent Electric

    MCap

    USD10m

    Last close

    USD1.61

    ▲ 0.30 (22.90%)

    SCHMID

    MCap

    USD267m

    Last close

    USD4.37

    ▲ 0.75 (20.72%)

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

  • Sectors

    Sectors

    View All Sectors
  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
testalize-me-0jE8ynV4mis-unsplash
Oryzon Genomics (BME: ORY) gains regulatory clearance for PMS trial of vafidemstat
Published by Arron Aatkar, PhD

Oryzon has received European authorisation to initiate a Phase IIa study of vafidemstat in Phelan McDermid Syndrome (PMS). The study has been designed to enrol 12 adult patients at one Spanish site, with safety and tolerability as the primary focus over 12 weeks of treatment. Changes in anger, aggression and other symptoms are secondary measures, offering an early indication of activity in a condition with no approved drugs at present. The rationale draws on findings in preclinical research in mice lacking SHANK3, and earlier exploratory clinical data in autism spectrum disorder. The study is partially funded through Med4Cure, and a Spanish patient association will help identify participants.

Next Sparks Commentary in this sector >

Latest

Consumer | Comment

Allwyn (ALWr.ASE) associate negatively affected by Brazil’s temporary prohibition on online sports betting and iGaming

Healthcare | Comment

OSE Immunotherapeutics (PAR: OSE) H126 update: Pipeline advances towards key milestones

Healthcare | Comment

Newron Pharmaceuticals (SIX: NWRN): ENIGMA-TRS2 advances in other countries while US on pause

Investment Companies | Comment

The Schiehallion Fund (LSE: MNTN/MNTS) reports 2026 interim results with a 29.1% NAV return

Investment Companies | Comment

Cordiant Digital Infrastructure (LSE: CORD) – AI contracts build as Q127 EBITDA growth phases as flagged
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.